Floatz logo

Xaliplatin

Periampullary Adenocarcinoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Periampullary Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Human Fibrinogen
Asan Medical Center
Phase 4BB
N-Butyl Cyanoacrylate
Minia University
Phase 3BB
Cediranib
National Cancer Institute (NCI)
Phase 2CCC
Cis-Diamminedichloroplatinum Ii
New Mexico Cancer Research Alliance
Phase 2CCC
Fluorouracilum
National Cancer Institute (NCI)
Phase 2CCC

View all 12 →

Same molecule, other indications

Xaliplatin is also rated in:

exocrine pancreatic carcinomaActive
BBB
Indicative · Phase 2/3
78 / 100
View asset →
colon adenocarcinomaActive
BBB
Indicative · Phase 3
77 / 100
View asset →
rectal cancerActive
BBB
Indicative · Phase 3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →